Genomic Signatures of MASLD: How Genomics Is Redefining Our Understanding of Metabolic Liver Disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver condition globally, driven by strong genetic and environmental components. This review summarizes recent advances in understanding the genetic architecture of MASLD. Genome-wide association studies (GWAS) have identified several key risk variants, primarily in genes such as PNPLA3, TM6SF2, GCKR, and MBOAT7, which influence hepatic lipid metabolism and disease progression. By utilizing surrogate markers of MASLD, researchers have also identified numerous putative MASLD-associated genes, warranting further investigation through functional genomics approaches. Next-generation sequencing techniques have uncovered rare variants in genes like APOB and ABCB4, as well as protective variants in HSD17B13 and CIDEB. This review discusses the potential of polygenic risk scores for disease stratification and the development of genetically informed therapeutic strategies. Additionally, it explores the future of functional genomics approaches in discovering novel treatment strategies. While the evolving genetic landscape of MASLD provides promising insights for precision medicine approaches in diagnosis, prognosis, and treatment, significant translational gaps remain. Addressing these challenges will be critical for realizing the full potential of personalised approaches in clinical management. This review synthesizes these findings and discusses their implications for future research and clinical practice in MASLD.

• Publication year

  2025

• Venue

  International Journal of Molecular Sciences

• Publication date

  2025-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3390/ijms262210881PMID 41303369PMCID 12652521
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.

  2024influential reference
• A functional genomic framework to elucidate novel causal metabolic dysfunction–associated fatty liver disease genes

  2024cited by this paper
• Genome-wide Studies Reveal Genetic Risk Factors for Hepatic Fat Content

  2024cited by this paper
• Genetics of MASLD: The State of Art Update.

  2024cited by this paper
• Supramolecular assembly boosting the phototherapy performances of BODIPYs

  2024cited by this paper
• Aramchol improves hepatic fibrosis in metabolic dysfunction–associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology

  2024cited by this paper
• Convergence of coronary artery disease genes onto endothelial cell programs

  2024cited by this paper
• A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease

  2023cited by this paper
• Advancements in metabolic‐associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions

  2023cited by this paper
• Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease

  2023cited by this paper
• Recent Progress of Supramolecular Chemotherapy Based on Host–Guest Interactions

  2023cited by this paper
• A global research priority agenda to advance public health responses to fatty liver disease.

  2023cited by this paper
• MBOAT7 rs641738 (C>T) is associated with NAFLD progression in men and decreased ASCVD risk in elder Chinese population

  2023cited by this paper
• Clinical utility of polygenic risk scores: a critical 2023 appraisal

  2023cited by this paper
• Machine learning prediction of the degree of food processing

  2023cited by this paper
• Multiomic Analysis and CRISPR Perturbation Screens Identify Endothelial Cell Programs and Novel Therapeutic Targets for Coronary Artery Disease.

  2023cited by this paper
• The clinical utility of polygenic risk scores in genomic medicine practices: a systematic review

  2022cited by this paper
• A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation

  2022cited by this paper
• Integration of genetic colocalizations with physiological and pharmacological perturbations identifies cardiometabolic disease genes

  2022cited by this paper
• Exome-wide association analysis of CT imaging-derived hepatic fat in a medical biobank

  2022cited by this paper
• Multiomics study of nonalcoholic fatty liver disease

  2022cited by this paper
• MBOAT7 rs641738 variant in metabolic-dysfunction-associated fatty liver disease and cardiovascular risk

  2022cited by this paper
• A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores.

  2021cited by this paper
• Machine learning enables new insights into genetic contributions to liver fat accumulation

  2021cited by this paper
• Integration of genetic colocalizations with physiological and pharmacological perturbations identifies cardiometabolic disease genes

  2021cited by this paper
• Identification and Optimization of a Minor Allele-Specific siRNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease

  2021cited by this paper
• Implementation and implications for polygenic risk scores in healthcare

  2021influential reference
• Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in nonalcoholic fatty liver disease

  2021cited by this paper
• Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort.

  2020cited by this paper
• Exome-wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated with Fatty Liver Disease.

  2020cited by this paper
• Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis

  2020cited by this paper
• Construction and Analysis of Protein-Protein Interaction Network of Non-Alcoholic Fatty Liver Disease

  2020cited by this paper
• Modeling Non-Alcoholic Fatty Liver Disease (NAFLD) Using “Good-Fit” Genome-Editing Tools

  2020cited by this paper
• Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores

  2020cited by this paper
• Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin‐Like Phospholipase Domain Containing 3–Mediated Acceleration of Steatohepatitis

  2020cited by this paper
• Leveraging polygenic enrichments of gene features to predict genes underlying complex traits and diseases

  2020cited by this paper
• Improving reporting standards for polygenic scores in risk prediction studies

  2020cited by this paper
• Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population

  2020cited by this paper
• A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH)

  2019cited by this paper
• Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice

  2019cited by this paper
• Analysis of polygenic risk score usage and performance in diverse human populations

  2019cited by this paper
• Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids.

  2019cited by this paper
• Obesity-linked suppression of membrane-bound O-acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease

  2019cited by this paper
• Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables

  2018cited by this paper
• A Protein‐Truncating HSD17B13 Variant and Protection from Chronic Liver Disease

  2018cited by this paper
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

  2018cited by this paper
• Patatin-like phospholipase domain–containing protein 3 promotes transfers of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets

  2018cited by this paper
• MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals

  2017cited by this paper
• Adiposity Amplifies the Genetic Risk of Fatty Liver Disease Conferred by Multiple Loci

  2017cited by this paper
• PNPLA3 expression and its impact on the liver: current perspectives

  2017cited by this paper
• Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

  2017cited by this paper
• Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.

  2016cited by this paper
• Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study1[S]

  2016cited by this paper
• The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent.

  2016cited by this paper
• Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

  2016cited by this paper
• Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease.

  2016cited by this paper
• The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe

  2016cited by this paper
• MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C

  2016cited by this paper
• EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease

  2016cited by this paper
• Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity

  2015cited by this paper
• Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant.

  2015cited by this paper
• Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease

  2015cited by this paper
• PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells

  2014cited by this paper
• Correction: Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease

  2014cited by this paper
• PNPLA3 mediates hepatocyte triacylglycerol remodeling[S]

  2014cited by this paper
• TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content

  2014cited by this paper
• Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta‐analysis of individual participant data

  2014cited by this paper
• Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.

  2014cited by this paper
• TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

  2014cited by this paper
• Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease

  2014cited by this paper
• Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease

  2014cited by this paper
• Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents

  2014cited by this paper
• PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome

  2014cited by this paper
• PNPLA3 I148M polymorphism and progressive liver disease.

  2013cited by this paper
• PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma

  2013cited by this paper
• Role of Patatin-Like Phospholipase Domain-Containing 3 on Lipid-Induced Hepatic Steatosis and Insulin Resistance in Rats

  2013cited by this paper
• Unraveling the genetics of fatty liver in obese children: Additive effect of P446L GCKR and I148M PNPLA3 polymorphisms

  2012cited by this paper
• PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis.

  2012cited by this paper
• Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase.

  2012cited by this paper
• Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis

  2012cited by this paper
• Hepatic Fat Accumulation Is Modulated by the Interaction between the rs738409 Variant in the PNPLA3 Gene and the Dietary Omega6/Omega3 PUFA Intake

  2012cited by this paper
• Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults

  2011cited by this paper
• Expression and Characterization of a PNPLA3 Protein Isoform (I148M) Associated with Nonalcoholic Fatty Liver Disease*

  2011cited by this paper
• Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits

  2011influential reference
• Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

  2011cited by this paper
• Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes.

  2011cited by this paper
• Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans.

  2011cited by this paper
• Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease

  2011cited by this paper
• A feed-forward loop amplifies nutritional regulation of PNPLA3

  2010cited by this paper
• The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status.

  2010cited by this paper
• Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease

  2010cited by this paper
• The association of genetic variability in patatin‐like phospholipase domain‐containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease

  2010cited by this paper
• A Sequence Variation (I148M) in PNPLA3 Associated with Nonalcoholic Fatty Liver Disease Disrupts Triglyceride Hydrolysis

  2009cited by this paper
• A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity

  2009cited by this paper
• Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

  2008cited by this paper
• European Association for the Study of the Liver

  2006cited by this paper
• Liver‐directed overexpression of mitochondrial glycerol‐3‐phosphate acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced fatty acid oxidation

  2006cited by this paper
• Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members Published, JLR Papers in Press, September 8, 2005. DOI 10.1194/jlr.M500290-JLR200

  2005cited by this paper
• Identification, Cloning, Expression, and Purification of Three Novel Human Calcium-independent Phospholipase A2 Family Members Possessing Triacylglycerol Lipase and Acylglycerol Transacylase Activities*

  2004cited by this paper
• Adiponutrin : a transmembrane protein corresponding to a novel dietary-and obesity-linked mRNA specifically expressed in the adipose lineage

  2001cited by this paper

• Linked Intronic Polymorphisms of the PNPLA3 Gene Are Associated with Serum Markers of Liver Injury in Patients with Spontaneous HCV Clearance

  2026cites this paper
• Obesity, Metabolic Dysfunction-Associated Steatotic Liver Disease and Hepatocellular Carcinoma: How Molecular Changes Impact Cellular Functions

  2026cites this paper